GlassScriptPhysician profile
Anne A Snider
NPI 1902887318
$4,676.93
in general payments reported to CMS, 2019-2025
20 companies · $862 in 2025
The $862 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $35.00 · 2021: $241 · 2022: $1,071 · 2023: $1,257 · 2024: $1,211 · 2025: $862.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,143 · Education: $187.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,142.52 |
| Education | $187.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $674.32 | 2020-2025 | Tremfya |
| Abbvie INC. | $674.00 | 2021-2025 | Skyrizi, Rinvoq |
| Sun Pharmaceutical Industries INC. | $479.25 | 2021-2025 | Ilumya, Winlevi, Absorica Ld |
| Ucb, INC. | $428.95 | 2022-2025 | Bimzelx, Briviact, Fintepla |
| Amgen INC. | $383.25 | 2022-2025 | Otezla, Otezla |
| Regeneron Healthcare Solutions, INC. | $304.95 | 2021-2025 | Dupixent |
| Lilly USA, LLC | $286.74 | 2020-2025 | Taltz, Olumiant, Ebglyss |
| Genzyme Corporation | $270.69 | 2022-2025 | |
| Galderma Laboratories, L.P. | $257.24 | 2022-2025 | Nemluvio, Aklief |
| Novartis Pharmaceuticals Corporation | $208.38 | 2021-2025 | |
| Pfizer INC. | $143.21 | 2022-2025 | |
| Incyte Corporation | $128.67 | 2022-2025 | Opzelura |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $97.56 | 2022-2024 | Jublia, Arazlo, Duobrii |
| Leo Pharma INC. | $94.50 | 2022-2025 | Adbry |
| Boehringer Ingelheim Pharmaceuticals, INC. | $72.18 | 2023-2024 | Spevigo, Cyltezo |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $67.15 | 2023-2024 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $64.41 | 2022-2023 | Sotyktu |
| Arcutis Biotherapeutics, INC. | $19.92 | 2023 | |
| Verrica Pharmaceuticals INC. | $15.85 | 2023 | Ycanth |
| Organon LLC | $5.71 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anne Snider listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.